Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20052592 | 0.76 | MEN1 (0.43) | KMT2ASMN1; SMN2MEN1LMNACA1 | |
| SCHEMBL9935086 | 0.76 | TAAR1 (0.52) | EPHX2POLBKMT2AGAANPC1 | |
| Hydrochloric Acid SCHEMBL696798 | 0.75 | TAAR1 (0.51) | EPHX2POLBKMT2AGAANPC1 | |
| SCHEMBL14511344 | 0.74 | HPGD (0.59) | HPGDEPHX2POLBKMT2AGAA | |
| SCHEMBL15356006 | 0.73 | TAAR1 (0.49) | EPHX2KMT2AGAANPC1RAB9A | |
| SCHEMBL9925290 | 0.72 | HPGD (0.62) | HPGDEPHX2POLBKMT2ANPC1 | |
| SCHEMBL20961904 | 0.72 | KMT2A (0.59) | HPGDEPHX2POLBKMT2AGAA | |
| SCHEMBL6289160 | 0.72 | HPGD (0.62) | HPGDEPHX2POLBKMT2AALDH1A1 | |
| SCHEMBL660115 | 0.72 | HPGD (0.62) | HPGDEPHX2POLBKMT2ANPC1 | |
| SCHEMBL6289159 | 0.72 | HPGD (0.62) | HPGDEPHX2POLBKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944635-B2 | Deuterated pyrazino[2,1-a]isoquinoline compounds and methods of treatment using the same | CONCERT PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160083385-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160060263-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | CONCERT PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9206179-B2 | Methods of use comprising deuterated pyrazino[2,1-a]isoquinolines | CONCERT PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9199986-B2 | Deuterated pyrazino[2,1-a]isoquinolines for the treatment of diseases and/or conditions | CONCERT PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150141431-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-8889687-B2 | Deuterated pyrazinoisoquinoline compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140107127-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2014-04-17 | — | — | US | disclosed |
| US-8563554-B2 | Deuterated pyrazinoisoquinoline compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130029997-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120149709-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141431-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | H1-5, MTX2, H1-4 | HPGD 918/4885EPHX2 512/4885POLB 2573/4885 |
| US-20130029997-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | H1-5, MTX2, H1-4 | HPGD 918/4885EPHX2 512/4885POLB 2573/4885 |
| US-20140107127-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | ACHE, ABCC5, ABCC2 | HPGD 887/4885EPHX2 306/4885POLB 3431/4885 |
| US-20160060263-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | P2RX5, ABCC5, ABCC2 | HPGD 718/4885EPHX2 156/4885POLB 3001/4885 |
| US-20120149709-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | P2RX5, ABCC5, ABCC2 | HPGD 718/4885EPHX2 156/4885POLB 3001/4885 |
| US-20160083385-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | H1-5, MTX2, H1-4 | HPGD 918/4885EPHX2 512/4885POLB 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.